ĐẶC ĐIỂM CƯỜNG CẬN GIÁP Ở BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TÍP 2 CÓ BỆNH THẬN MẠN GIAI ĐOẠN CUỐI LỌC MÁU CHU KỲ

Abstract

Objectives: To determine the prevalence of hyperparathyroidism in patients with type 2 diabetes mellitus (T2DM) and end-stage renal disease (ESRD) undergoing hemodialysis at the Center for Nephrology, Urology, and Hemodialysis, Bach Mai Hospital, and to describe the clinical, laboratory characteristics, and related factors of hyperparathyroidism in this patient group. Patients and method: A random sample of 107 patients with T2DM undergoing hemodialysis at the Center for Nephrology, Urology, and Hemodialysis, Bach Mai Hospital, from July 2024 to July 2025. Results: The prevalence of hyperparathyroidism in T2DM patients undergoing hemodialysis was 57.0%, with an average parathyroid hormone (PTH) level of 39.99 ± 25.68 pmol/L. There was a strong correlation between PTH, calcium, and phosphorus levels. Common clinical symptoms included pruritus, blurred vision, and numbness/sensory disturbances. Conclusion: Hyperparathyroidism is a common complication in T2DM patients undergoing hemodialysis, necessitating early detection and timely treatment.